Copyright
©The Author(s) 2017.
World J Hepatol. Sep 8, 2017; 9(25): 1043-1053
Published online Sep 8, 2017. doi: 10.4254/wjh.v9.i25.1043
Published online Sep 8, 2017. doi: 10.4254/wjh.v9.i25.1043
Risk | Drug class |
High (> 10%) | B-cell depleting agents |
Anthracycline | |
Corticosteroids high dose | |
Moderate (1%-10%) | TNFα inhibitors |
Cytokine and integrin inhibitors | |
Tyrosine kinase inhibitors | |
Corticosteroids moderate dose | |
Low (< 1%) | Corticosteroids low dose |
Traditional immunosuppression (e.g., azathioprine or methotrexate) |
- Citation: Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053
- URL: https://www.wjgnet.com/1948-5182/full/v9/i25/1043.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i25.1043